http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101214433-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7042 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7042 |
| filingDate | 2006-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101214433-B1 |
| titleOfInvention | Condensed heterocyclic derivatives, pharmaceutical compositions containing the same and uses thereof |
| abstract | The present invention is expressed by the following general formula (I), which expresses human SGLT activity inhibitory activity and is useful as a prophylactic or therapeutic agent for diseases caused by hyperglycemia, such as diabetes, postprandial hyperglycemia, abnormal glucose tolerance, diabetic complications, obesity, and the like. Nitrogen-containing condensed ring derivatives or pharmacologically acceptable salts thereof, or prodrugs thereofn n n (R 1 and R 4 are either one of the groups represented by general formula (S) (R 5 and R 6 are H, OH, a halogen atom, etc .; Q is an alkylene group; ring A is an aryl group, etc.), the other Side is H, OH, an amino group, etc .; R 2 and R 3 are H, OH, an amino group, a halogen atom, a substitutable alkyl, and the like; A 1 is O, S, or the like; A 2 is CH, or N; G is a group represented by the following general formula (G-1) or (G-2) (E 1 is H, F or OH; E 2 is H, F, methyl group, etc.), and a pharmaceutical composition containing the same and its It is to provide a medical use.n n n SGLT activity inhibitory effect, hyperglycemia, condensed heterocyclic derivative |
| priorityDate | 2004-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1305.